SCHEMBL2499741

SCHEMBL2499741

Cc1c(-c2cnc3ccc(OCCO[Si](C)(C)C(C)(C)C)cn23)sc(C(=O)O)c1OCC[C@@]1(Cl)C=CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2500397 0.80 TBXAS1 (0.30)
SCHEMBL2499006 0.68 PLK1 (0.33)
SCHEMBL2496366 0.67 FYN (0.31)
SCHEMBL2504629 0.66 DGAT1 (0.34)
SCHEMBL2500399 0.65 PLK1 (0.34)
SCHEMBL2497128 0.64 PLK1 (0.41)
SCHEMBL2495143 0.64 FYN (0.40)
SCHEMBL2504943 0.61 DUT (0.34)
SCHEMBL2498512 0.61 PLK1 (0.53)
SCHEMBL2496370 0.59 KDM4E (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed